SERENA-2

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

SERENA-2

Nov 8, 2024, 06:58 | Insight

Elisa Agostinetto: Camizestrant vs Fulvestrant for estrogen receptor-positive, HER2-negative breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…

May 18, 2024, 04:17 | Blog

Sara Tolaney: Interesting data from Mafalda Oliveira from SERENA-2 at ESMO Breast24

Sara Tolaney shared a post on X: ''Interesting data from Mafalda Oliveira from SERENA-2 demonstrating…

May 18, 2024, 04:13 | Blog

Elisa Agostinetto: Is this a new predictive biomarker for PFS with camizestrant

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023